Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DNA, Xoma long-term Raptiva data

Genentech (DNA) and partner XOMA reported open-label data for their Raptiva efalizumab to treat moderate to severe psoriasis that DNA said could support long-term

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE